A Cross-Sector Call to Improve Carcinogenicity Risk Assessment Through Use of Genomic Methodologies


Robust genomic approaches are now available to realize improvements in efficiencies and translational relevance of cancer risk assessments for drugs and chemicals. The authors propose a path for implementation of innovative cancer risk assessment including incorporating genomic signatures to assess mechanistic relevance of carcinogenicity and enhanced use of genomics in benchmark dose and point of departure evaluations. Novel opportunities for the chemical and pharmaceutical sectors to combine expertise, resources, and objectives to achieve a common goal of improved human health protection are identified.

Abstract text online: https://www.sciencedirect.com/science/article/abs/pii/S0273230019302909